Skip to main content

Sitting Pretty

Premium

As genomics stocks bottom out, here’s who’s still on top

$7.1M William Rich, Ciphergen, CEO

$63.1M Mark Chandler, Luminex, CEO

$213.3M Lyle Turner, Invitrogen, CEO

$2.7M Mark Boguski, Rosetta Inpharmatics, Sr. VP of R&D

$6.9M William Matthews, Deltagen, CEO

$4.9M Mark Gessler, Gene Logic, CEO

$1.8M Stuart Collinson, Aurora Biosciences, CEO

$8.7M Howard Birndorf, Nanogen, CEO

$66.8M Mark Chee, Illumina, VP of Genomics

$76.0M Tony White, Applera, CEO

$5.3M Arthur sands, Lexicon Genetics, CEO

$6.3M Gregg Helt, Affymetrix, Principal Scientist

$1.3M Dale Pfost, Orchid BioSciences, President and CEO

$8.4M Cyrus Harmon, Affymetrix, VP of Computational Genomics

$1.7M John King, Rosetta Inpharmatics, COO

$9.7M Timothy Rink, Aurora Biosciences, Fmr. Chrm. and CEO

$40.5M Michael Hunkapiller, Applied Biosystems, President

$2.6M Tony Shuh, Sequenom, President and CEO

$4.1M Daniel Kisner, Caliper Technologies, CEO

$8.5M Stephen Fodor, Affymetrix, CEO

$1.1M Kieran Gallahue, Nanogen, CFO

$17.1M Roy Whitfield, Incyte Genomics, CEO

$42.2M Craig Venter, Celera Genomics, CSO

$15.3M Harden McConnell, Molecular Devices, Founder

$3.2M Calvin Chow, Caliper Technologies, COO

$3.9M Hannes Smarason, DeCode Genetics, Sr. Bus. & Finance Officer

$4.8M Joseph Keegan, Molecular Devices, CEO

$14.6M Emery Olcott, Packard Bioscience, CEO

$4.9M Joseph Limber, Aclara BioSciences, CEO

$18.4M Dennis Winger, Applied Biosystems, CFO

$2.9M Herbert Hooper, Aclara BioSciences, CSO

$38.8M Jeffrey Williams, Genomic Solutions, CEO

$21.9M Kari Stefansson, DeCode Genetics, CEO

$7.2M Jay Flatley, Illumina, CEO

$8.8M Randy Scott, Incyte Genomics, Chairman

$10.0M Richard McKernan, Packard BioScience, Sr. VP

$3.4M Jeffrey Gulcher, DeCode Genetics, VP, R&D

$5.9M Stephan Friend, Rosetta Inpharmatics, CEO

Values reflect individuals’ fully diluted company shares and options. All data based on most recent SEC filings available and March 29 share prices.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.